About: Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients
Creator	Wang, Fu-Sheng Xiang, Charlie Schreiber, Martin Bunnell, Bruce Harman, Robert Minev, Boris Rogers, Christopher Santidrian, Antonio
Source	Medline; PMC
abstract	In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per day. Less than 100 days later, the World Health Organization declared that the rapidly spreading viral outbreak had become a global pandemic. Coronavirus disease 2019 (COVID-19) is typically associated with fever and respiratory symptoms. It often progresses to severe respiratory distress and multi-organ failure which carry a high mortality rate. Older patients or those with medical comorbidities are at greater risk for severe disease. Inflammation, pulmonary edema and an over-reactive immune response can lead to hypoxia, respiratory distress and lung damage. Mesenchymal stromal/stem cells (MSCs) possess potent and broad-ranging immunomodulatory activities. Multiple in vivo studies in animal models and ex vivo human lung models have demonstrated the MSC’s impressive capacity to inhibit lung damage, reduce inflammation, dampen immune responses and aid with alveolar fluid clearance. Additionally, MSCs produce molecules that are antimicrobial and reduce pain. Upon administration by the intravenous route, the cells travel directly to the lungs where the majority are sequestered, a great benefit for the treatment of pulmonary disease. The in vivo safety of local and intravenous administration of MSCs has been demonstrated in multiple human clinical trials, including studies of acute respiratory distress syndrome (ARDS). Recently, the application of MSCs in the context of ongoing COVID-19 disease and other viral respiratory illnesses has demonstrated reduced patient mortality and, in some cases, improved long-term pulmonary function. Adipose-derived stem cells (ASC), an abundant type of MSC, are proposed as a therapeutic option for the treatment of COVID-19 in order to reduce morbidity and mortality. Additionally, when proven to be safe and effective, ASC treatments may reduce the demand on critical hospital resources. The ongoing COVID-19 outbreak has resulted in significant healthcare and socioeconomic burdens across the globe. There is a desperate need for safe and effective treatments. Cellular based therapies hold great promise for the treatment of COVID-19. This literature summary reviews the scientific rationale and need for clinical studies of adipose-derived stem cells and other types of mesenchymal stem cells in the treatment of patients who suffer with COVID-19.
has issue date	2020-05-18(xsd:dateTime)
bibo:doi	10.1186/s12967-020-02380-2
bibo:pmid	32423449
has license	cc-by
sha1sum (hex)	d166a55438ba79729e783c0fe45f08e88dc7177f
schema:url	https://doi.org/10.1186/s12967-020-02380-2
resource representing a document's title	Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients
has PubMed Central identifier	PMC7232924
has PubMed identifier	32423449
schema:publication	J Transl Med
resource representing a document's body	covid:d166a55438ba79729e783c0fe45f08e88dc7177f#body_text
is schema:about of	named entity 'administration' named entity 'intravenous' named entity 'mesenchymal stem cells' named entity 'therapies' named entity 'possess' named entity 'healthcare' named entity 'declared' named entity 'reduced' named entity 'demonstrated' named entity 'reduce' named entity 'effective' named entity 'The' named entity 'mesenchymal stem cells' named entity 'respiratory illnesses' named entity 'inflammation' named entity 'COVID-19' named entity 'outbreak' named entity 'activities' named entity 'emerged' named entity 'studies' named entity 'ASC' named entity 'based' named entity 'antimicrobial' named entity 'morbidity' named entity 'pulmonary disease' named entity 'demonstrated' named entity 'lung' named entity 'respiratory distress' named entity 'capital city' named entity 'vivo' named entity 'COVID-19' named entity 'Hubei' named entity 'suffer' named entity 'COVID-19' named entity 'Coronavirus disease 2019' named entity 'immunomodulatory' named entity 'stem cells' named entity 'socioeconomic' named entity 'antimicrobial' named entity 'animal models' named entity 'lung' named entity 'mortality rate' named entity 'clinical studies' named entity 'intravenous administration' named entity 'COVID-19 outbreak' named entity 'reduce inflammation' named entity 'coronavirus' named entity 'COVID-19 disease' named entity 'adipose-derived' named entity 'morbidity' named entity 'acute respiratory distress syndrome' named entity 'immune responses' named entity 'pulmonary function' named entity 'respiratory illnesses' named entity 'COVID' named entity 'respiratory symptoms' named entity 'Older patients' named entity 'cells' named entity 'Mesenchymal' named entity 'CD8 +' named entity 'lungs' named entity 'plasma' named entity 'IL-10' named entity 'ICU' named entity 'anticoagulation' named entity 'ARDS' named entity 'EQ-5D' named entity 'MSCs' named entity 'extracellular matrix' named entity 'vaccine' named entity 'CD19' named entity 'randomized trial' named entity 'E. coli' named entity 'cytokines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software